Antimicrobial resistance with Streptococcus pneumoniae in the United States

Seminars in Respiratory and Critical Care Medicine

Volumn 21, Issue 4, 2000, Pages 273-284

  Doern, G V ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Antimicrobial resistance; Pneumococcal; Streptococcus pneumoniae

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; CEFACLOR; CEFDINIR; CEFIXIME; CEFOTAXIME; CEFPODOXIME; CEFPROZIL; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CETHROMYCIN; CHLORAMPHENICOL; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN; GATIFLOXACIN; LEVOFLOXACIN; LINEZOLID; LORACARBEF; MACROLIDE; MOXIFLOXACIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINUPRISTIN; TELITHROMYCIN; TETRACYCLINE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; NONHUMAN; PENICILLIN RESISTANCE; PRIORITY JOURNAL; REVIEW; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

EID: 0033846064     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-9863     Document Type: Review

References (90)

1. Emergence of multiply resistant pneumococci
2. Antimicrobial resistance of Streptococcus pneumoniae in the United States, 1997-1987
3. Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States
4. Increasing penicillin resistance in Streptococcus pneumoniae in the U.S. Effect on susceptibility to oral cephalosporins
5. In vitro activities of 21 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. medical centers in 1992 and 1993
6. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: Results of a 30-center national surveillance study
7. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 Results from the SENTRY Antimicrobial Surveillance Program
8. Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997-98
9. Variation in penicillin-binding protein patterns of penicillin-resistant clinical isolates of pneumococci
10. Penicillin-binding proteins 2b and 2x of Streptococcus pneumoniae are primary resistance determinants for different classes of β-lactam antibiotics
11. Five independent combinations of mutations can result in low-affinity penicillin-binding protein 2x of Streptococcus pneumoniae
12. Penicillin binding protein 2x as a major contributor to intrinsic β-lactam resistance of Streptococcus pneumoniae
13. Alterations of PBP 1A essential for high-level penicillin resistance in Streptococcus pneumoniae
14. Alterations in penicillin-binding protein 2B from penicillin-resistant wild-type strains of Streptococcus pneumoniae
15. Multiple changes of penicillin-binding proteins in penicillin-resistant clinical isolates of Streptococcus pneumoniae
16. Horizontal transfer of penicillin-binding protein genes in penicillin-resistant clinical isolates of Streptococcus pneumoniae
17. Penicillin-resistant viridans streptococci have obtained altered penicillin-binding protein genes from penicillin-resistant strains of Streptococcus pneumoniae
18. Interspecies recombinational events during the evolution of altered PBP 2X genes in penicillin-resistant clinical isolates of Streptococcus pneumoniae
19. Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States
20. Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates causing systemic infections in Spain, 1979-1989
21. Antimicrobial resistance in Streptococcus pneumoniae. An epidemiological survey in France, 1970-1990
22. Trends in antimicrobial resistance of clinical isolates of Streptococcus pneumoniae in Bellvitge Hospital, Barcelona, Spain (1979-1990)
23. Extremely high incidence of antibiotic resistance in clinical isolates of Streptococcus pneumoniae in Hungary
24. Pneumococcal antimicrobial resistances: The problem in Hungary
25. Management of infections due to antibiotic-resistant Streptococcus pneumoniae
26. Minireview: Management of meningitis caused by penicillin-resistant Streptococcus pneumoniae
27. Risk factors and response to antibiotic therapy in adults with bacteremic pneumonia caused by penicillin-resistant pneumococci
28. Comparison of the response to antimicrobial therapy of penicillin-resistant and penicillin-susceptible pneumococcal disease
29. Susceptibility of Streptococcus pneumoniae to penicillin: A prospective microbiologic and clinical study
30. Relationship of MICs to efficacy of cefotaxime in treatment of Streptococcus pneumoniae infections
31. Resistance to penicillin and cephalosporins and mortality from severe pneumococcal pneumonia in Barcelona, Spain
32. Cephalosporin treatment failure in penicillin- and cephalosporin-resistant Streptococcus pneumoniae meningitis
33. Dilemmas in diagnosis and management of cephalosporin-resistant Streptococcus pneumoniae meningitis
34. Emergence of vancomycin tolerance in Streptococcus pneumoniae
35. Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae from the cerebrospinal fluid of a patient who developed recrudescent meningitis
36. Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: A common resistance pattern mediated by an efflux system
37. Novel mechanism of macrolide resistance in Streptococcus pneumoniae
38. Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistant surveillance study conducted in the United States in 1994-1995
39. Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia
40. Efficacy and tolerability of once-daily grepafloxacin compared with clarithromycin in the treatment of acute bacterial exacerbations of chronic bronchitis
41. Etiology, susceptibility, and treatment of acute bacterial exacerbations of complicated chronic bronchitis in the primary care setting: Ciprofloxacin 750 mg BID versus clarithromycin 500 mg BID
42. Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia
43. Fluoroquinolone resistance with S. pneumoniae in the United States
44. In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis
45. The prevalence of fluoroquinolone resistance among clinically significant respiratory tract isolates of Streptococcus pneumoniae in the United States and Canada. 1997 Results from the SENTRY Antimicrobial Surveillance Program
46. Pharmacodynamics of levofloxacin. A new paradigm for early clinical trials
47. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada
48. In vitro activities of a streptogramin (RP59500), three macrolides, and an azalide against four respiratory tract pathogens
49. In vitro activity of RP 59500 (quinu-pristin/dalfopristin) against antibiotic-resistant strains of Streptococcus pneumoniae and enterococci
50. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents
51. In vitro activities of oxazo-lidinones U-100592 and U-100766 against penicillin-resistant and cephalosporin-resistant strains of Streptococcus pneumoniae
52. In vitro activity of the novel ketolide HMR 3647 and comparative oral antibiotics against Canadian respiratory tract isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis
53. In vitro activities of the new ketolide antibiotics HMR 3004 and HMR 3647 against Streptococcus pneumoniae in Germany
54. The in vitro activity of ABT-773, a new ketolide antimicrobial agent, against recent clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis
55. The epidemiology of pneumococcal disease in infants and children
56. Pneumococcal resistance to antibiotics
57. Serotype distribution of penicillin-resistant pneumococci and their susceptibilities to seven antimicrobial agents
58. Clonal relationships among high-level penicillin-resistant Streptococcus pneumoniae in the United States
59. Clonal relationships among antimicrobial-resistant Streptococcus pneumoniae in the United States
60. Septic siblings with pneumonia due to penicillin-resistant Streptococcus pneumoniae
61. Carriage of multidrug-resistant Streptococcus pneumoniae and impact of chemoprophylaxis during an outbreak of meningitis at a day care center
62. Clonal and temporal patterns of nasopharyngeal penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae strains in children attending a day care center
63. The spread of multiply resistant Streptococcus pneumoniae at a day care center in Ohio
64. Transmission of multidrug-resistant serotype 23F Streptococcus pneumoniae in group day care: Evidence suggesting capsular transformation of the resistant strain in vivo
65. Molecular epidemiology of Streptococcus pneumoniae with decreased susceptibility to penicillin in Paris children's hospital
66. Penicillin-resistant Streptococcus pneumoniae strains recovered in Houston: Identification and molecular characterization of multiple clones
67. Evidence for a clonal origin of relative penicillin resistance among type 9L pneumococci in northwestern Canada
68. The three major Spanish clones of penicillin-resistant Streptococcus pneumoniae are the most common clones recovered in recent cases of meningitis in Spain
69. Identification of multiple clones of extended-spectrum cephalosporin-resistant Streptococcus pneumoniae isolates in the United States
70. Genetic relatedness within and between serotypes of Streptococcus pneumoniae from the United Kingdom: Analysis of multilocus enzyme electrophoresis, pulsed-field gel electrophoresis, and antimicrobial resistance patterns
71. Major related sets of antibiotic-resistant pneumococci in the United States as determined by pulsed-field gel electrophoresis and pbp1a-pbp2b-pbp2x-dhf restriction profiles
72. Spread of drug-resistant Streptococcus pneumoniae in Asian countries: Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study
73. Analysis of multiply antimicrobial-resistant isolates of Streptococcus pneumoniae from the United States
74. Evidence for the introduction of a multiresistant clone of serotype 6B Streptococcus pneumoniae from Spain to Iceland in the late 1980s
75. Geographic distribution of penicillin-resistant clones of Streptococcus pneumoniae. Characterization by penicillin-binding protein profile, surface protein A typing, and multilocus enzyme analysis
76. Intercontinental spread of a multiresistant clone of serotype 23F Streptococcus pneumoniae
77. Penicillin-binding protein families: Evidence for the clonal nature of penicillin resistance in clinical isolates of pneumococci
78. Multiply resistant pneumococcus causing meningitis: Its epidemiology within a day care center
79. A review of antibiotic resistance patterns of Streptococcus pneumoniae in Europe
80. High prevalence of multidrug-resistant Streptococcus pneumoniae among children in a rural Kentucky community
81. Limiting the spread of penicillin-resistant Streptococcus pneumoniae. Experiences from the south Swedish pneumococcal intervention project
82. Effects of cefixime or co-amoxiclav treatment on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae in children with acute otitis media
83. Pneumococcal resistance patterns in Europe
84. Effect of antimicrobial use and other risk factors on antimicrobial resistance in pneumococci
85. Relationship between antimicrobial usage in metropolitan statistical areas and changes in resistance of Streptococcus pneumoniae at 23 hospitals nationwide
86. Antimicrobial susceptibility of nasopharyngeal isolates of potential pathogens recovered from infants before antibiotic therapy: Implications for the management of otitis media
87. A prospective study of the impact of community-based azithromycin treatment of trachoma on carriage and resistance of Streptococcus pneumoniae
88. Minimizing the impact of drug-resistant Streptococcus pneumoniae (DRSP)